Citations

Clear

5 citation(s) found for "Subias, M P Escribano".

A19-10 Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 3 PROSERA Trial
Ghofrani, H A, Mclaughlin, V V, Meyer, G Bohns, Benza, R L, Channick, R N, Chin, K M, Frantz, R P, Hemnes, A R, Howard, L S, Zamanian, R T, Kopeć, G, Skride, A, Jerjes-Sánchez, C, Lescano, A J, Subías, M P Escribano, White, R J, Zamudio, T Pulido, Perna, E R, Rosenkranz, S, Badagliacca, R, Scelsi, L, Lima, M A, Sulica, R, Miller, C, Al-Hiti, H, Campos, F, Zagolin, M, Roscigno, R F, Mottola, D, Aranda, R, Cravets, M, Tompkins, C -A A, Parsley, E, Elman, E, Zisman, L S, Vachiery, J L, Sitbon, O, Ghofrani, H A, McLaughlin, Vallerie V. , Meyer, Gisela Martina Bohns , Benza, Raymond L. , Channick, R N, Chin, K M, Frantz, Robert P. , Hemnes, A R, Howard, L S, Zamanian, R.T., Kopeć, Grzegorz , Skride, Andris , Jerjes‐Sánchez, Carlos , Subias, M P Escribano, White, R. James , Perna, Eduardo , Rosenkranz, S, Badagliacca, Roberto , Scelsi, Laura , Sulica, Roxana, Miller, Chad E., Al‐Hiti, Hikmet, Roscigno, Robert F., Mottola, David, Aranda, R, Cravets, Matt , Parsley, Ed, Elman, Erin, Zisman, Lawrence S. , Vachiéry, Jean‐Luc , Sitbon, Olivier

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 22, 2026 | Volume: 212 | Issue: Supplement_2 | Pages: No page available

10.1093/ajrccm/aamag286.279 Get It

Abstract Rationale Seralutinib is an investigational, first-in-class tyrosine kinase inhibitor designed for inhalation and selective for PDGFRα, PDGFRβ, CSF1R, and cKIT, targeting proliferation, inflammation, and fibrosis ─ three core drivers of pulmonary vascular remodeling in PAH. The phase 2 TORREY trial of seralutinib added to standard-of-care treatment in adults with PAH WHO FC II or III met its primary endpoint of a statistically significant reduction in pulmonary vascular resistance (PVR) vs. placebo at 24 weeks. Methods PROSERA (NCT05934526), a phase 3, randomized, double-blind, placebo-controlled, multicenter trial, evaluated the efficacy and safety of inhaled seralutinib in PAH patients treated for up to 48 weeks. Eligible patients (WHO Group 1 PH, FC II or III; REVEAL Lite 2 Risk Score ≥5 or NT-proBNP ≥300 ng/L or PVR ≥800 dyne•s/cm5) on standard background therapy were randomized 1:1 to seralutinib 90 mg or placebo delivered by dry powder inhaler twice daily. The primary endpoint was change in six-minute walk distance (6MWD) from baseline to week 24 in the seralutinib treatment group vs. placebo. Key secondary endpoints included: time to clinical worsening (TTCW), proportion of patients with clinical improvement at week 24, change in NT-proBNP from baseline to week 24, and proportion of patients with ≥1-point decrease from baseline in REVEAL Lite 2 Risk Score at week 24. Safety endpoints included incidence of treatment-emergent adverse events (TEAEs) and serious TEAEs (SAEs). Patients who completed blinded treatment could be eligible to participate in an open-label extension study. Preliminary Blinded Results 390 patients were randomized at 132 sites worldwide. At baseline, mean age was 50.0 years. PAH etiologies included 61.0% idiopathic, 9.7% heritable, and 22.3% associated with connective tissue disease. 25.6% of patients were WHO FC II and 74.4% FC III. Mean time from diagnosis was TBD years. Most patients were receiving 2 (39.2%) or ≥ 3 (54.6%) PAH medications, 29.2% were receiving parenteral prostacyclin. Baseline PVR was 798.4 dyne•s/cm5, 6MWD was 373.7 m, and NT-proBNP was 986.8 ng/L. The difference in 6MWD from baseline to week 24 between seralutinib and placebo was TBD [SD] m (p=TBD). Secondary endpoints of TTCW, clinical improvement, NT-proBNP, and REVEAL Lite 2 Risk Score will be reported. The most common AEs were TBD (x%) and TBD (y%). SAEs and discontinuations related to AE will be reported. Conclusions The PROSERA study demonstrates⋯ [to be updated following unblinding of the data]. Funding Gossamer Bio, Inc. This abstract is funded by: Gossamer Bio, Inc.
Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Zolty, R., Kingrey, J.F. , Penn, Benjamin G., Sobol, Irina , Sood, Namita , Benza, R.L., Channick, Richard, Frantz, R, McLaughlin, V.V., Vachiéry, J, Zamanian, R.T., Cravets, Matt , Roscigno, Robert F., Mottola, David, Parsley, Ed, Aranda, R., Zisman, Lawrence S. , Ghofrani, Hossein Ardeschir , Sahay, Sandeep , Subías, Pilar Escribano , Penn, B, Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804612 Get It

Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Zolty, Ronald , Kingrey, J.F. , Penn, Benjamin G., Sobol, Irina , Sood, Namita , Benza, R.L., Channick, Richard N. , McLaughlin, Vallerie V. , Vachiéry, Jean‐Luc , Zamanian, R.T., Cravets, Matt , Roscigno, R.F., Mottola, David, Parsley, E., Aranda, R., Zisman, Lawrence S. , Investigators, on behalf of the TORREY Study, Sitbon, Olivier , Sahay, Sandeep , Subías, Pilar Escribano , Penn, B., Channick, Richard N. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , McLaughlin, Vallerie V. , Ghofrani, Hossein Ardeschir

Mayo Clinic

A14. BUILDING LEGO(LAND): LESSONS LEARNED FROM LARGE SCALE CLINICAL TRIALS IN PAH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1011-A1011

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1011 Get It

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial
McLaughlin, V.V., Zolty, Ronald , Channick, Richard N. , Chin, K. , Vachiéry, Jean‐Luc , Zamanian, R.T., Cravets, Matt , Roscigno, R.F., Mottola, David, Elman, Erin, Parsley, E., Aranda, R., Zisman, Lawrence S. , Investigators, on behalf of the TORREY Study, Frantz, Robert P. , Sahay, Sandeep , Subías, Pilar Escribano , Benza, Raymond L. , Channick, Richard N. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier , Ghofrani, Hossein Ardeschir

Mayo Clinic

D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6726-A6726

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6726 Get It

Pulmonary Arterial Hypertension: Epidemiology and Registries
McGoon, Michael D., Subías, Pilar Escribano , Humbert, Marc

Mayo Clinic

Advances in Pulmonary Hypertension | February 26, 2019 | Volume: 13 | Issue: 1 | Pages: 21-26

10.21693/1933-088x-13.1.21 Get It

Registries of pulmonary arterial hypertension (PAH) are important means by which to characterize the presentation and outcome of patients and to provide a basis for predicting the course of the disease. This article summarizes the published conclusions of the World Symposium of Pulmonary Hypertension task force that addressed registries and epidemiology of PAH.